We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| 10X Capital Venture Acquisition Corp III | NYSE:VCXB | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0 | - |
Filed by 10X Capital Venture Acquisition Corp. III pursuant to
Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934, as amended
Subject Company: 10X Capital Venture Acquisition Corp. III
(Commission File No. 001-41216)
Date: October 11, 2023
American Gene Technologies® to Present at ROTH MKM 2023 Healthcare Opportunities Conference
Rockville, MD, October 11, 2023 -- American Gene Technologies® (AGT™), a clinical-stage biotechnology company dedicated to improving human health through innovative gene and cell therapies, today announced that Jeff Galvin, Founder and Chief Executive Officer, will present at the ROTH MKM Healthcare Opportunities Conference held at The Yale Club in New York City, New York, on October 12, 2023. Management will also be available for one-on-one meetings.
Event: ROTH MKM Healthcare Opportunities Conference
Location: The Yale Club in New York City, NY
Formal Presentation: Thursday, October 12, 1:15pm ET
On August 9, 2023, AGT announced its entry into a merger agreement with 10X Capital Venture Acquisition Corp. III (10X III; (NYSE: VCXB)). Pursuant to the merger agreement, AGT intends to merge its HIV business with 10X III. Following the merger, the combined company will be renamed Addimmune™ and will focus on progressing AGT’s lead clinical asset, AGT103-T, and other potential therapeutic candidates aimed at improving the lives of people living with HIV. Prior to the merger, AGT will spin off its non-HIV business into a newly formed entity, which is expected to retain and operate under the AGT name.
About American Gene Technologies
American Gene Technologies (AGT) is a leading biotechnology company at the forefront of genetic science, dedicated to improving human health through innovative gene and cell therapies. AGT is committed to harnessing the power of genetic science to develop cutting-edge solutions that help to alleviate human suffering and improve the quality of life for individuals affected by devastating diseases. With a commitment to excellence in science and patient care, AGT is pioneering the future of medicine. For more, visit www.americangene.com.
Media Contact:
Grant Smith
Vice President of Marketing and Communications
American Gene Technologies
317-518-9807
gsmith@americangene.com
1 Year 10X Capital Venture Acqu... Chart |
1 Month 10X Capital Venture Acqu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
